BRIEF published on 01/27/2025 at 22:20, 1 year 8 months ago Theralase's Interim Clinical Data to be Highlighted at 2025 AUA Annual Meeting Clinical Data Theralase Bladder Cancer Light-activated Therapy Urological Innovations
PRESS RELEASE published on 01/27/2025 at 22:15, 1 year 8 months ago Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting Theralase announces interim clinical data presentation at AUA Annual Meeting, showcasing promising results of light-activated Ruvidar™ in treating BCG-Unresponsive NMIBC CIS Theralase Bladder Cancer Interim Clinical Data Light-activated Ruvidar AUA Annual Meeting
BRIEF published on 12/09/2024 at 14:10, 1 year 9 months ago Theralase Expands Clinical Study Sites for Bladder Cancer Treatment in the U.S. Cancer Research Bladder Cancer Treatment Theralase Expansion Clinical Study Sites Ruvidar Activation
BRIEF published on 12/09/2024 at 14:10, 1 year 9 months ago Theralase élargit ses sites d'études cliniques pour le traitement du cancer de la vessie aux États-Unis Recherche Sur Le Cancer Expansion De La Théralase Traitement Du Cancer De La Vessie Sites D'études Cliniques Activation De Ruvidar
PRESS RELEASE published on 12/09/2024 at 14:05, 1 year 9 months ago Theralase(R) Launches Three New Clinical Study Sites in USA Theralase® launches new US Clinical Study Sites for bladder cancer treatment. Principal Investigators announced. Positive clinical data presented Clinical Data Theralase® Bladder Cancer US Clinical Study Sites
BRIEF published on 12/05/2024 at 13:05, 1 year 9 months ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
BRIEF published on 12/05/2024 at 13:05, 1 year 9 months ago Theralase Technologies étend son étude sur le cancer de la vessie au Canada Étude Clinique Cancer De La Vessie Ruvidar Technologies Théralase Expansion Au Canada
PRESS RELEASE published on 12/05/2024 at 13:00, 1 year 9 months ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 year 10 months ago Theralase publie son aperçu financier du troisième trimestre 2024 Placements Privés Dépenses De Recherche Et Développement Aperçu Financier De Theralase Chiffre D'affaires Et Marges Résultats De L'étude II
BRIEF published on 11/27/2024 at 23:10, 1 year 10 months ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
Published on 10/02/2026 at 13:50, 1 day 12 hours ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 13 hours ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 13 hours ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/03/2026 at 15:45, 10 hours 55 minutes ago Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 1 day 2 hours ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 6 hours ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 6 hours ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 19:00, 1 day 7 hours ago INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 10/02/2026 at 17:45, 1 day 8 hours ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 1 day 8 hours ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 1 day 9 hours ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 1 day 9 hours ago Aéroports de Paris SA - Calendrier financier 2027
